Cerenome (CNSY) vs Citius Pharmaceuticals (CTXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Cerenome (CNSY) over the past year, losing 62.0% versus a loss of 90.5%. Over five years, CTXR leads with a -99.1% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($13.6 million vs $13.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | CTXR |
|---|---|---|
| Share price | $1.79 | $0.4887 |
| Market cap | $13.59M | $13.42M |
| 1-day change | +9.48% | -2.47% |
| YTD return | -85.96% | -37.10% |
| 1-year return | -90.45% | -61.97% |
| 5-year return | -99.73% | -99.06% |
| EPS (TTM) | $-3.36 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $2.19 |
| 52-week low | $1.49 | $0.469 |
| Distance from 52-week high | -90.58% | -77.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1450.28% | +718.50% |
| Average volume | 121.12K | 527.79K |
| Shares outstanding | 7.59M | 27.45M |
| Employees | 28 | 23 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed CNSY by 28.5 percentage points over the past year.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Healthcare · Biotechnology · 28 employees
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Healthcare · Biotechnology · 23 employees
CNSY vs CTXR FAQ
Which is bigger, Cerenome or Citius Pharmaceuticals?
Cerenome (CNSY) is larger, with a market capitalization of $13.59M compared with $13.42M for Citius Pharmaceuticals (CTXR).
Which stock has performed better over the past year, CNSY or CTXR?
CTXR returned -61.97% over the past 12 months, compared with -90.45% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and Citius Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.